Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

about

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone Remarkable regression of a giant cell tumor of the cervical spine treated conservatively with denosumab: A case report.

P2860

Q28066533-86ECBD6D-D9E2-4CA6-A04E-EB971B4DC8D8 Q36918666-104EFB6B-68F1-4F01-88CF-C34AA7025240

P2860

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

Item

http://www.wikidata.org/entity/Q41061051

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

@en

type

Item

label

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

@en

prefLabel

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

@en

P1476

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

@en

P2093

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

Lizz van der Heijden

http://www.w3.org/2001/XMLSchema#string

P D Sander Dijkstra

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment and outcome of giant cell tumors of the pelvis

Giant cell tumor of bone: risk factors for recurrence.

Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB

Giant cell tumors of the axial skeleton.

Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature.

Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy.

P304

393-395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/17453674.2014.1002345

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pancras C.W. Hogendoorn

Michiel Adreanus van de Sande

P577

2015-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273905649

http://www.w3.org/2001/XMLSchema#string

P698

25684041

http://www.w3.org/2001/XMLSchema#string

P932

4443461

http://www.w3.org/2001/XMLSchema#string

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

about

P2860

P2860

Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932